219 related articles for article (PubMed ID: 23823605)
1. Use of phosphate-binding agents is associated with a lower risk of mortality.
Cannata-Andía JB; Fernández-Martín JL; Locatelli F; London G; Gorriz JL; Floege J; Ketteler M; Ferreira A; Covic A; Rutkowski B; Memmos D; Bos WJ; Teplan V; Nagy J; Tielemans C; Verbeelen D; Goldsmith D; Kramar R; Martin PY; Wüthrich RP; Pavlovic D; Benedik M; Sánchez JE; Martínez-Camblor P; Naves-Díaz M; Carrero JJ; Zoccali C
Kidney Int; 2013 Nov; 84(5):998-1008. PubMed ID: 23823605
[TBL] [Abstract][Full Text] [Related]
2. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
3. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.
Komaba H; Wang M; Taniguchi M; Yamamoto S; Nomura T; Schaubel DE; Smith AR; Zee J; Karaboyas A; Bieber B; Fukagawa M; Tentori F
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1489-1497. PubMed ID: 28724618
[TBL] [Abstract][Full Text] [Related]
4. Design and baseline characteristics of the LANDMARK study.
Ogata H; Fukagawa M; Hirakata H; Kaneda H; Kagimura T; Akizawa T;
Clin Exp Nephrol; 2017 Jun; 21(3):531-537. PubMed ID: 27405619
[TBL] [Abstract][Full Text] [Related]
5. Cardiac troponin T elevation at dialysis initiation is associated with all-cause and cardiovascular mortality on dialysis in patients without diabetic nephropathy.
Hayashi T; Kimura T; Yasuda K; Sasaki K; Obi Y; Rakugi H; Isaka Y
Clin Exp Nephrol; 2017 Apr; 21(2):333-341. PubMed ID: 27178276
[TBL] [Abstract][Full Text] [Related]
6. Serum phosphate and mortality in incident dialysis patients in Australia and New Zealand.
Tiong MK; Ullah S; McDonald SP; Tan SJ; Lioufas NM; Roberts MA; Toussaint ND
Nephrology (Carlton); 2021 Oct; 26(10):814-823. PubMed ID: 34046973
[TBL] [Abstract][Full Text] [Related]
7. Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients.
Merle E; Roth H; London GM; Jean G; Hannedouche T; Bouchet JL; Drüeke T; Fouque D; Daugas E;
Kidney Int; 2016 Mar; 89(3):666-74. PubMed ID: 26880460
[TBL] [Abstract][Full Text] [Related]
8. Practice patterns of phosphate binder use and their associations with mortality in chronic kidney disease.
Navaneethan SD; Sakhuja A; Arrigain S; Sharp J; Schold JD; Nally JV
Clin Nephrol; 2014 Jul; 82(1):16-25. PubMed ID: 24887302
[TBL] [Abstract][Full Text] [Related]
9. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
10. Use of Phosphorus Binders among Non-Dialysis Chronic Kidney Disease Patients and Mortality Outcomes.
Bhandari SK; Liu IA; Kujubu DA; Huynh T; Behayaa H; Kovesdy CP; Kalantar-Zadeh K; Jacobsen SJ; Sim JJ
Am J Nephrol; 2017; 45(5):431-441. PubMed ID: 28445887
[TBL] [Abstract][Full Text] [Related]
11. Phosphate management in chronic kidney disease.
Bhan I
Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):174-9. PubMed ID: 24445424
[TBL] [Abstract][Full Text] [Related]
12. Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD-ROUTE study.
Iimori S; Naito S; Noda Y; Nishida H; Kihira H; Yui N; Okado T; Sasaki S; Uchida S; Rai T
Nephrology (Carlton); 2015 Sep; 20(9):601-8. PubMed ID: 25917812
[TBL] [Abstract][Full Text] [Related]
13. Phosphate control in reducing FGF23 levels in hemodialysis patients.
Rodelo-Haad C; Rodríguez-Ortiz ME; Martin-Malo A; Pendon-Ruiz de Mier MV; Agüera ML; Muñoz-Castañeda JR; Soriano S; Caravaca F; Alvarez-Lara MA; Felsenfeld A; Aljama P; Rodriguez M
PLoS One; 2018; 13(8):e0201537. PubMed ID: 30086150
[TBL] [Abstract][Full Text] [Related]
14. Oral phosphate binders in CKD - is calcium the (only) answer?
Goldsmith D; Covic A
Clin Nephrol; 2014 Jun; 81(6):389-95. PubMed ID: 25017668
[TBL] [Abstract][Full Text] [Related]
15. Association of serum chloride level with mortality and cardiovascular events in chronic kidney disease: the CKD-ROUTE study.
Mandai S; Kanda E; Iimori S; Naito S; Noda Y; Kikuchi H; Akazawa M; Oi K; Toda T; Sohara E; Okado T; Sasaki S; Rai T; Uchida S
Clin Exp Nephrol; 2017 Feb; 21(1):104-111. PubMed ID: 27039905
[TBL] [Abstract][Full Text] [Related]
16. Patients with diabetes as the primary kidney disease have a worse survival than patients with comorbid diabetes in chronic haemodialysis patients.
Chen HC; Chou CY; Hsiao YT; Liang CC; Kuo HL; Chang CT; Liu JH; Wang IK; Huang CC
Nephrology (Carlton); 2015 Mar; 20(3):155-60. PubMed ID: 25487855
[TBL] [Abstract][Full Text] [Related]
17. Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study.
Sakaguchi Y; Fujii N; Shoji T; Hayashi T; Rakugi H; Iseki K; Tsubakihara Y; Isaka Y;
PLoS One; 2014; 9(12):e116273. PubMed ID: 25545498
[TBL] [Abstract][Full Text] [Related]
18. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients.
Liabeuf S; Lenglet A; Desjardins L; Neirynck N; Glorieux G; Lemke HD; Vanholder R; Diouf M; Choukroun G; Massy ZA;
Kidney Int; 2012 Dec; 82(12):1297-303. PubMed ID: 22895515
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
[TBL] [Abstract][Full Text] [Related]
20. Serum phosphorus in people with chronic kidney disease: you are what you eat.
Tonelli M
Kidney Int; 2013 Nov; 84(5):871-3. PubMed ID: 24172733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
